Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945761 | 0.89 | HTR7 (0.44) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL23744120 | 0.88 | CYP2D6 (0.45) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL23744263 | 0.87 | CHRM1 (0.54) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL26429313 | 0.86 | CHRM4 (0.58) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL26429298 | 0.86 | GPR119 (0.49) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL26429299 | 0.86 | GPR119 (0.49) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL23744809 | 0.86 | CYP2D6 (0.42) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL24945665 | 0.85 | MAPK1 (0.45) | CYP3A4TSHRALDH1A1CYP2C9CHRM4 | |
| SCHEMBL26087084 | 0.85 | CHRM2 (0.56) | CYP3A4TSHRCHRM4USP2CHRM5 | |
| SCHEMBL23744205 | 0.85 | CHRM4 (0.56) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CYP3A4 269/4885TSHR 131/4885ALDH1A1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.